Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.52 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.45 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.44 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1002485 | 1.00 | ADRB2 (0.52) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL19205719 | 1.00 | ADRB2 (0.52) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| SCHEMBL382596 | 0.98 | ADRB2 (0.54) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| SCHEMBL13666761 | 0.98 | ADRB2 (0.54) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| SCHEMBL2032469 | 0.98 | ADRB2 (0.54) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| SCHEMBL148751 | 0.98 | ADRB2 (0.54) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| SCHEMBL30504213 | 0.98 | ADRB2 (0.54) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| SCHEMBL11747206 | 0.87 | OPRM1 (0.50) | ADRB2PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL4592741 | 0.85 | ADRB2 (0.52) | ADRB2PNMTLMNAOPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL4413207 | 0.81 | ADRB2 (0.54) | ADRB2PNMTLMNAOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119522208-A | Effective methods for modulating NMDA receptor-mediated toxicity | 智基药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-113271950-B | Pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-3909584-B1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-116368136-A | EGFR inhibitors | 大鹏药品工业株式会社 | 2023-06-30 | — | — | CN | disclosed |
| EP-4197538-A1 | EGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-06-21 | — | — | EP | disclosed |
| EP-4183395-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| EP-3909584-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-11-17 | — | — | EP | disclosed |
| CN-113271950-A | Pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-08-17 | — | — | CN | disclosed |
| US-11078207-B2 | Substituted pyrrolo[2,3-d]pyrimidines as HER2 inhibitors | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210024530-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
| WO-2020145374-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2020-07-16 | — | — | WO | disclosed |
| US-9133140-B2 | Cycloalkylamne derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2341044-B1 | CYCLOALKYLAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-02-26 | — | — | EP | disclosed |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | MARUMOTO SHINJI (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2341044-A1 | CYCLOALKYLAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024530-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, EGFR, ERBB4 | ADRB2 1671/4885OPRM1 1492/4885OPRD1 2535/4885 |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | ADRB2 16/4885OPRM1 769/4885OPRD1 348/4885 |
| US-11078207-B2 | Substituted pyrrolo[2,3-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | ADRB2 1579/4885OPRM1 1272/4885OPRD1 1467/4885 |
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | ADRB2 3408/4885OPRM1 2989/4885OPRD1 2818/4885 |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TYMP, DPYD, TYMS | ADRB2 3749/4885OPRM1 3647/4885OPRD1 4178/4885 |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | ADRB2 16/4885OPRM1 769/4885OPRD1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.